{
 "about": "海外 VC / 投资机构自己写的女性健康（硬件）文章：投资备忘、赛道论点、市场地图、年度预测、赛道报告，每篇打开原文核对过标题、日期、作者。gist 是核心观点的中文转述，不是原文；seg 对应 layers.json 的 code，all = 赛道总论。",
 "articles": [
  {
   "t": "Osteoboost（Our Investment Thesis）",
   "org": "Disrupt Technology Venture（Disrupt Ignite）",
   "au": "",
   "date": "2026-11-02",
   "url": "https://www.disruptignite.com/portfolio/osteoboost",
   "seg": [
    "f6"
   ],
   "co": [
    "Osteoboost Health"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "该基金给了三条理由：骨量低是治疗空白，Osteoboost 是唯一获 FDA 批准的相关穿戴；长寿与预防是顺风；延缓绝经后骨量流失能挡住骨折连锁后果。",
   "vs": "部分",
   "why": "处方级可穿戴能进更年期，但卖的是治疗，不是连续测量加算法结论",
   "cav": "页面无日期与作者，date 为检索日期，不是发布日；是 portfolio 条目，篇幅短。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Nuvo（Why VentureIsrael invested）",
   "org": "VentureIsrael",
   "au": "",
   "date": "2026-11-02",
   "url": "https://ventureisrael.com/portfolio/nuvo.md",
   "seg": [
    "f3"
   ],
   "co": [
    "Nuvo INVU"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "VentureIsrael 称投 Nuvo 是因为它把产前护理从被动监测推向预测式智能，并积累了最大的母胎心率信号数据集，可训练更早识别并发症的 AI。",
   "vs": "一致",
   "why": "居家穿戴加连续信号加算法给结论，正是图谱判断在孕期的版本",
   "cav": "页面无日期与作者，date 为检索日期；打开的是 .md 版本；「最大数据集」等说法是该基金自己的，无数据出处。",
   "r": 2,
   "top": 1
  },
  {
   "t": "How a $527 billion growth opportunity in women's health can improve health outcomes",
   "org": "Deloitte",
   "au": "Deloitte Center for Health Solutions",
   "date": "2026-09-29",
   "url": "https://www.deloitte.com/us/en/insights/industry/health-care/womens-health-growth-better-outcomes.html",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "研究报告",
   "region": "海外",
   "gist": "Deloitte 用约 6000 万人的理赔数据建模：若转向主动、按人生阶段的预防与早筛，2030 年美国女性健康可多出约 5270 亿美元潜在支出。脑健康、盆底、心血管、肌骨与自身免疫四块需求与市场最吻合。",
   "vs": "部分",
   "why": "主张主动、分阶段预防与早筛，但是需求建模，没有谈可穿戴",
   "cav": "页面作者栏未读到具体姓名，作者署为发布部门；报道称作者含 Jen Radin、Andy Davis。是需求建模，不是融资数据。",
   "r": 1,
   "top": 0
  },
  {
   "t": "Beyond the Ring: Why We Invested in Ultrahuman",
   "org": "Qualcomm Ventures",
   "au": "Anirvan Chowdhury",
   "date": "2026-09-24",
   "url": "https://www.qualcommventures.com/insights/blog/beyond-the-ring-why-we-invested-in-ultrahuman/",
   "seg": [
    "f9"
   ],
   "co": [
    "Ultrahuman Ring（Cycle & Ovulation Pro）"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "高通创投领投 Ultrahuman 7000 万美元轮：认为智能戒指是最适合持续监测的穿戴形态，投的是从被动追踪走向个性化健康智能，再往后是边缘 AI 下的新一代人机界面。",
   "vs": "无关",
   "why": "全文没提女性或经期，只旁证戒指加连续信号加 AI 的大趋势",
   "cav": "投资方重点是计算平台而非健康；Ultrahuman 总部在印度。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Oura revenue, valuation & funding",
   "org": "Sacra",
   "au": "",
   "date": "2026-09",
   "url": "https://sacra.com/c/oura/",
   "seg": [
    "f9"
   ],
   "co": [
    "Oura"
   ],
   "kind": "研究报告",
   "region": "海外",
   "gist": "Sacra 称女性健康是 Oura 最深的平台投入，覆盖怀孕、围绝经期、避孕药支持和更年期洞察，并接入 Midi、Evernow、Maven、Progyny；收入约 80% 硬件、20% 订阅。",
   "vs": "一致",
   "why": "把女性健康写成通用穿戴的平台级增长点",
   "cav": "页面无日期，内容引用 2026-09-03 的 S-1，故写到月；无署名；部分数据为 Sacra 估算，完整内容需注册。",
   "r": 2,
   "top": 0
  },
  {
   "t": "$70m/yr Oura of India",
   "org": "Sacra",
   "au": "Jan-Erik Asplund",
   "date": "2026-09",
   "url": "https://sacra.com/research/ultrahuman-oura-of-india/",
   "seg": [
    "f9"
   ],
   "co": [
    "Ultrahuman Ring（Cycle & Ovulation Pro）"
   ],
   "kind": "研究报告",
   "region": "海外",
   "gist": "Sacra 称 Ultrahuman 定位为不收订阅费的 Oura 替代品，用「Power Plugs」微订阅（排卵追踪约每月 4 美元）变现，约 12% 用户付费。",
   "vs": "部分",
   "why": "女性功能已成为通用穿戴的付费模块，但商业模式分歧大",
   "cav": "页面标 Updated Sep 2, 2026，无首发日；全文需注册，只读到免费部分；Ultrahuman 在印度。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Global Wearable Breast Pump Industry（白皮书介绍页）",
   "org": "Frost & Sullivan",
   "au": "",
   "date": "2026-09",
   "url": "https://go.frost.com/tgp/hls/wearablebreastpump_sep26",
   "seg": [
    "f4"
   ],
   "co": [
    "Momcozy",
    "Willow",
    "Elvie（Willow）"
   ],
   "kind": "研究报告",
   "region": "海外",
   "gist": "Frost 称穿戴式吸奶器 2025 年零售额 10 亿美元、610 万台，成熟市场转向换新升级，低渗透市场仍有首购空间；比较 Momcozy、Willow、Elvie 的产品与地域。",
   "vs": "部分",
   "why": "说明吸乳穿戴是跑通的细分，但页面只讲规模，没谈连续监测与算法",
   "cav": "只读到白皮书介绍页，本体需留资下载；日期取自 URL 中 sep26。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Healthcare business ideas that sound great but don't scale. Part 2: AI women's health apps",
   "org": "Heal Capital（Healthtech Off The Record 投资人 Substack）",
   "au": "Dr. Lucas Mittelmeier",
   "date": "2026-08-09",
   "url": "https://healthtechofftherecord.substack.com/p/healthcare-business-ideas-that-sound-84b",
   "seg": [
    "f2"
   ],
   "co": [
    "Clair Health"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "作者认为 AI 女性周期 app 是被过度推销的点子：数据、解读、治疗、交付四层里只有交付层成熟，激素难测、研究缺口大；不看好用腕带间接推断激素，只看好直接测量，并称新医疗硬件动辄数亿美元、稀释大，与基金十年期冲突，VC 更容易接受药物模式。",
   "vs": "相反",
   "why": "明说腕带推断激素是猜而不是测，且硬件融资结构上难做",
   "cav": "页面无日期，08-09 取自搜索索引；投资人身份以署名「Fresh off the dealflow at Heal Capital」为准，未另查头衔。",
   "r": 2,
   "top": 1
  },
  {
   "t": "Why FemTech Needs to Move Beyond Wellness Apps（Women Disrupting Tech 第 161 期，嘉宾 Karen Berg）",
   "org": "Healthy.Capital（嘉宾所在 VC）",
   "au": "Karen Berg（嘉宾）；整理 Dirkjan Hupkes",
   "date": "2026-07-15",
   "url": "https://womendisruptingtech.substack.com/p/episode-161",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "播客访谈",
   "region": "海外",
   "gist": "Berg 认为 femtech 做 wellness app 是因为容易，真问题需要真诊断；把 FDA、MDR、CE 批准当护城河和有效性证据，并指出女性健康数据稀缺，限制了 AI 能做的事。",
   "vs": "部分",
   "why": "投资人买单的是过监管、有诊断级证据的产品，不是 wellness 级推断穿戴",
   "cav": "第三方播客的文字整理页，引文是转述的嘉宾原话；页面无日期，07-15 取自检索（另一页面标 07-16）；Healthy.Capital 为荷兰基金。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Last week I wrote about how little money reaches women's health（Fiona Wong LinkedIn 长帖）",
   "org": "Zaz Ventures",
   "au": "Fiona Wong",
   "date": "2026-07-09",
   "url": "https://www.linkedin.com/posts/fionawongdt_womenshealth-deeptech-femtech-activity-7481249336606048256-ed9Z",
   "seg": [
    "f2",
    "f6"
   ],
   "co": [],
   "kind": "市场分析",
   "region": "海外",
   "gist": "Zaz 的投资人提醒：不少腕戴围绝经期“激素追踪”设备其实并不测激素，只是用皮温、心率、汗液与周期做相关，却被当成测激素来卖，消费级设备监管又松，夸大会消耗女性健康刚得来的关注。她认为真正的缺口是更简单的诊断和组织/激素层面的基础数据，资金要覆盖整个周期而非易做的一端。",
   "vs": "相反",
   "why": "指出腕戴围绝经期设备并不测激素，只是相关推断，被当测量卖",
   "cav": "LinkedIn 帖，无标题，标题取首句；日期取自检索索引，页面无日期；Zaz Ventures 为非北美机构（Womed 为被投案例，非硬件可穿戴）。",
   "r": 1,
   "top": 0
  },
  {
   "t": "The Other Half of Health",
   "org": "PeakBridge VC",
   "au": "Dr. Gali Artzi, Nurit Ben",
   "date": "2026-06-22",
   "url": "https://peakbridge.vc/the-other-half-of-health/",
   "seg": [
    "f6"
   ],
   "co": [
    "Midi Health",
    "Maven Clinic"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "PeakBridge 称女性健康正从粉色 wellness 转向有临床、可报销的类别；更年期等赛道里单品和零售模式被挤压（文中称 DTC 获客成本五年涨约 60%、留存约 28%），平台和 B2B2C 才复利，文中估值与退出例子全是临床服务平台，没有硬件。",
   "vs": "部分",
   "why": "资本叙事押在临床平台与服务，穿戴不在主线里",
   "cav": "页面无日期，06-22 取自检索；全文不讨论可穿戴，只能当钱流向服务的侧证。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Two Stanford grads raise $11M to build a noninvasive wearable for hormone tracking（Emily Bennett LinkedIn 帖）",
   "org": "a16z speedrun",
   "au": "Emily Bennett",
   "date": "2026-06-16",
   "url": "https://www.linkedin.com/posts/emilybennett1_two-stanford-grads-raise-11m-to-build-a-activity-7473098847880298496-mlK4",
   "seg": [
    "f2"
   ],
   "co": [
    "Clair Health"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "a16z speedrun 自 pre-seed 起投 Clair。他们的判断：女性长期缺少关于自己身体的数据，Clair 要做的是女性健康缺失的“数据层”，并称赞团队执行速度。",
   "vs": "一致",
   "why": "把 Clair 看作女性健康缺失的数据层",
   "cav": "这是投资人 LinkedIn 短帖，不是长文；日期取自检索索引，页面无日期；Emily Bennett 的职位页面未写明。",
   "r": 1,
   "top": 0
  },
  {
   "t": "Inside Emmeline Ventures' Fertility Report",
   "org": "Emmeline Ventures",
   "au": "Emmeline Ventures 团队",
   "date": "2026-06-15",
   "url": "https://emmelineventures.substack.com/p/inside-emmeline-ventures-fertility",
   "seg": [
    "f1"
   ],
   "co": [],
   "kind": "研究报告",
   "region": "海外",
   "gist": "Emmeline 称其生育健康图谱收录 257 家公司，已披露融资超 92.8 亿美元，近 60% 为女性创立，趋势是新诊断技术、数字平台扩面、生殖寿命。",
   "vs": "无关",
   "why": "只列趋势，没提可穿戴",
   "cav": "报告介绍帖，完整报告未打开；日期 archive 写 06-16，检索为 06-15。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Innovation in Women's Health 2026",
   "org": "SVB（First Citizens）",
   "au": "Megan Scheffel, Adam Tweedy, Nina Kandilian, Alex Lennox-Miller, Josh Pherigo, Urbashee Paul",
   "date": "2026-06",
   "url": "https://www.svb.com/trends-insights/reports/womens-health-report/",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "研究报告",
   "region": "海外",
   "gist": "SVB 数据：2025 年美欧女性健康风投约 20 亿美元，较 2024 年高点回落，预计 2026 年反弹；2019 年以来女性特有疾病公司累计 62 亿美元。AI 赋能的公司估值约为同行 3 倍，钱集中在预测并预防高成本事件的临床工具上，且疾病若也影响男性更容易拿到钱。",
   "vs": "部分",
   "why": "钱集中在 AI 临床工具，文中没有把可穿戴作为主线",
   "cav": "页面无明确发布日，月份取自 Norwest 2026-06-17 引用及媒体报道；2025 版 PDF 两个链接均 404，未收。",
   "r": 1,
   "top": 1
  },
  {
   "t": "Women driving healthcare consumerization with data and capital（LinkedIn 帖）",
   "org": "Capital F（合伙人帖）",
   "au": "Dawn Dobras",
   "date": "2026-05-30",
   "url": "https://www.linkedin.com/posts/dawndobras_womenshealth-femaleeconomy-venturecapital-activity-7466985539829669888-2bUG/",
   "seg": [
    "f9"
   ],
   "co": [
    "Oura",
    "Midi Health"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "帖子称 60% 的 Oura 用户为女性，Midi 患者 100% 为女性，Function Health 会员超半数为女性；作者说 AI 正在释放女性健康数据，Capital F 的方向是女性健康消费化。",
   "vs": "一致",
   "why": "把 Oura 与个人健康数据栈当作消费化主线",
   "cav": "页面无日期，05-30 取自检索；Dobras 的 Capital F 身份由帖内措辞推断，页面未写职务。",
   "r": 2,
   "top": 0
  },
  {
   "t": "（LinkedIn 帖）Oura 是自 2019 年以来第一家申请 IPO 的女性健康公司",
   "org": "Second Opinion Media（Christina Farr 个人帖）",
   "au": "Christina Farr",
   "date": "2026-05-22",
   "url": "https://www.linkedin.com/posts/christinafarr_hot-take-%C5%8Dura-is-the-first-womens-health-activity-7463636989771329536-pB7W",
   "seg": [
    "f9"
   ],
   "co": [
    "Oura"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "Farr 认为女性是 Oura 的核心人群，真正的生意是订阅续费，硬件收入只是入场券；Oura 为此招医生、与 Maven、Evernow 合作并做了女性健康专用 AI 模型。",
   "vs": "一致",
   "why": "明确把指环看作女性健康最大的生意之一",
   "cav": "日期由帖子 ID 反推，页面无日期；未在页面核实她的现任机构头衔；评论区有人持反对意见。",
   "r": 2,
   "top": 1
  },
  {
   "t": "Access; the New Innovation in FemTech",
   "org": "Emmeline Ventures",
   "au": "Emmeline Ventures 团队",
   "date": "2026-05-20",
   "url": "https://emmelineventures.substack.com/p/access-the-new-innovation-in-femtech",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "市场分析",
   "region": "海外",
   "gist": "Emmeline 称 2024 年女性健康初创约融资 26 亿美元（转引 SVB），主论点是下一波增长来自可及性和可负担性，例如 IVF 每周期 1.5 万到 2.5 万美元。",
   "vs": "部分",
   "why": "论点是降价扩面，只提到远程监测",
   "cav": "页面无日期，05-20 取自 archive；数据几乎全是转引。",
   "r": 2,
   "top": 0
  },
  {
   "t": "The Hormonal Health Market: An Emmeline Ventures Map of the Hormonal Health Ecosystem（LinkedIn 帖）",
   "org": "Emmeline Ventures（合伙人帖）",
   "au": "La Keisha Landrum Pierre",
   "date": "2026-04-19",
   "url": "https://www.linkedin.com/posts/lnlpierre_hormonal-health-research-activity-7451980524799045632-yMT1",
   "seg": [
    "f2"
   ],
   "co": [
    "Eli Health",
    "Hertility"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "帖子称图谱分析了 100 家激素健康公司，追踪融资 218.5 亿美元，覆盖诊断、疗法、可穿戴和综合护理平台；女性独立创始人拿走 73.5%。",
   "vs": "部分",
   "why": "可穿戴被列为四类之一，但没拆分其融资与进展",
   "cav": "页面无日期，04-19 取自检索；73.5% 可能被个别大公司拉高，未核实；图谱本体未打开。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Why women's health could be health care's next boom",
   "org": "Deloitte",
   "au": "Kulleni Gebreyes",
   "date": "2026-04-16",
   "url": "https://www.deloitte.com/us/en/industries/life-sciences-health-care/blogs/health-care/why-womens-health-could-be-health-cares-next-boom.html",
   "seg": [
    "all"
   ],
   "co": [
    "Oura"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "Deloitte 分析 PitchBook：2025 年健康科技风投涨近 30%，女性健康却降 56%（约 12 亿到 4.78 亿美元），但估值仍在涨，说明钱在向更少、更成熟的公司集中。文中称 Oura 加入经期与孕期功能后估值翻倍，诊断、数字平台和联网设备是近期增长主力。",
   "vs": "部分",
   "why": "称联网设备是增长主力，但同文显示 2025 年女性健康融资大降",
   "cav": "Deloitte 是咨询公司，非 VC，按 BRIEF 作行业分析收入。",
   "r": 1,
   "top": 0
  },
  {
   "t": "The Endometriosis Innovation Economy",
   "org": "Emmeline Ventures",
   "au": "Emmeline Ventures 团队",
   "date": "2026-04-08",
   "url": "https://emmelineventures.substack.com/p/the-endometriosis-innovation-economy",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "研究报告",
   "region": "海外",
   "gist": "Emmeline 称分析了 19 国 75 家子宫内膜异位症公司，市场机会 1800 亿至 2500 亿美元，女性创始人占 56%；只讲诊断、药物和护理。",
   "vs": "无关",
   "why": "没有可穿戴论点",
   "cav": "页面无日期，04-08 取自检索；同页数字前后有出入（690.5 亿对 689.6 亿），引用时留意。",
   "r": 2,
   "top": 0
  },
  {
   "t": "WHOOP",
   "org": "Collaborative Fund",
   "au": "Craig Shapiro",
   "date": "2026-03-31",
   "url": "https://collabfund.com/blog/whoop/",
   "seg": [
    "f9"
   ],
   "co": [
    "Whoop（周期与孕期洞察）"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "领投 Whoop Series G 的 term sheet 信：现行医疗模式是被动、片段式的，可穿戴要做「人体的软件层」，用 24 小时连续监测、AI 教练和医疗级设备连接消费端与临床端。该基金称这是其最大的一笔投资。",
   "vs": "部分",
   "why": "连续监测取代诊所快照的逻辑支持图谱判断，但全文没提女性",
   "cav": "页面正文无日期，署名日期 2026-03-31 为页面所读（搜索索引标 03-30）；全文无女性相关词，只能旁证大叙事。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Making Hormone Intelligence Visible: Why We Invested in Clair",
   "org": "Reach Capital",
   "au": "",
   "date": "2026-02-04",
   "url": "https://www.reachcapital.com/resources/news/hormone-intelligence-made-visible-why-we-invested-in-clair-health/",
   "seg": [
    "f2"
   ],
   "co": [
    "Clair Health"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "Reach 认为激素是女性健康里最看不见的一块：现在只有抽血化验的“快照”或靠体温推算的粗略工具。Clair 不是给现有手环加功能，而是从零设计传感器 + 多模态机器学习，从体液、心率变异、体温等信号推断激素，所以他们投。",
   "vs": "一致",
   "why": "为从零设计的传感器加多模态模型推断激素投资",
   "cav": "页面没有署名，作者栏留空；Clair 是推断激素而非直接测量，文中未给验证数据。",
   "r": 1,
   "top": 1
  },
  {
   "t": "FemTech at Scale: The Growth Era",
   "org": "Emmeline Ventures",
   "au": "Emmeline Ventures 团队",
   "date": "2026-01-22",
   "url": "https://emmelineventures.substack.com/p/femtech-at-scale-the-growth-era",
   "seg": [
    "all"
   ],
   "co": [
    "Maven Clinic",
    "Flo Health",
    "Midi Health"
   ],
   "kind": "年度预测",
   "region": "海外",
   "gist": "Emmeline 转引 Astute Analytica 称 2025 年全球 FemTech 市场 631.4 亿美元、设备与诊断占收入 45.46%，转引 PitchBook 称 2024 年约 12 到 13 亿美元融资、177 笔交易，并把可穿戴监测与居家诊断套件列为最大收入来源。",
   "vs": "一致",
   "why": "文中把可穿戴监测列为最大收入来源",
   "cav": "数字全是转引第三方，Astute 口径未核对；页面无日期，01-22 取自 archive。",
   "r": 2,
   "top": 0
  },
  {
   "t": "A New Year, Already in Motion",
   "org": "Emmeline Ventures",
   "au": "",
   "date": "2026-01-12",
   "url": "https://emmelineventures.substack.com/p/a-new-year-already-in-motion",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "年度预测",
   "region": "海外",
   "gist": "Emmeline 预判 2026 年女性健康靠数字赋能和综合护理：文中称 58% 的雇主计划扩大女性预防和更年期福利，数字女性健康年复合增速 20% 以上；做法要贴合支付方行为、靠合作而不是单打独斗。",
   "vs": "部分",
   "why": "看好数字赋能，但不专讲硬件",
   "cav": "不专讲硬件，数字均为文中引用；Substack 页面日期为检索索引，作者未署名。",
   "r": 1,
   "top": 0
  },
  {
   "t": "Why Women's Health Gets Just Two Percent of VC Funding And What We Are Doing About It",
   "org": "Portfolia",
   "au": "",
   "date": "2025-12-12",
   "url": "https://www.portfolia.co/blogs/why-womens-health-gets-just-two-percent-of-vc-funding-and-what-we-are-doing-about-it",
   "seg": [
    "all"
   ],
   "co": [
    "Osteoboost Health"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "Portfolia 引用 SVB 称女性健康只拿到约 2% 的医疗风投，却占 80% 的家庭医疗决策；认为问题在于投资人构成和把它当垂直小赛道，应当视为横跨全医疗的视角。文中点了更年期、子宫内膜异位、骨质疏松、心血管几块被低估的机会，并以其 46 家女性健康被投公司作证。",
   "vs": "无关",
   "why": "讲融资缺口与被低估的病种，没谈形态",
   "cav": "页面无署名；带募资宣传口吻；2% 数字是文中引用 SVB 2025 版。",
   "r": 1,
   "top": 0
  },
  {
   "t": "Tough Love for Women's Health Founders（嘉宾 Lisa Suennen）",
   "org": "The Billion Dollar Blindspot（嘉宾为 Go Red for Women Venture Fund）",
   "au": "Lisa Suennen（嘉宾）",
   "date": "2025-11-06",
   "url": "https://blog.billiondollarblindspot.com/p/tough-love-for-womens-health-founders",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "播客访谈",
   "region": "海外",
   "gist": "节目说明称 Suennen 在 AHA 基金几个月内看了 500 多份女性健康融资材料，女性健康常卡在 A 轮；建议融资时讲的是股权而不是产品。",
   "vs": "无关",
   "why": "讲融资策略，不涉及形态",
   "cav": "只有节目说明页，无逐字稿；日期取自 Podscan 页。",
   "r": 2,
   "top": 0
  },
  {
   "t": "From Ring to Revolution: Oura Becomes an $11 Billion Company",
   "org": "Forerunner Ventures",
   "au": "Eurie Kim",
   "date": "2025-10-14",
   "url": "https://www.forerunnerventures.com/perspectives/from-ring-to-revolution-oura-becomes-an-11-billion-company",
   "seg": [
    "f9"
   ],
   "co": [
    "Oura"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "Forerunner 回头讲当年领投 Oura 是押「睡眠是健康根基」，把戒指看成从被动治病转向主动健康的日常入口；文中称已售 550 万枚、年收入有望 10 亿美元、订阅约占营收 20%。女性健康只作为平台延伸功能带过。",
   "vs": "部分",
   "why": "支持「可穿戴是健康主入口」，但女性只是延伸功能，不是论点",
   "cav": "女性相关只有几处带过（孕期、产后、女性健康功能），不提经期与更年期；数字为 Forerunner 自己的口径。",
   "r": 2,
   "top": 1
  },
  {
   "t": "Masterclass: Inside the Deal—Why We Said Yes to Oura",
   "org": "Alumni Ventures",
   "au": "David Shapiro",
   "date": "2025-07-09",
   "url": "https://www.av.vc/blog/masterclass-inside-the-deal-why-we-said-yes-to-oura-7-9-25",
   "seg": [
    "f9"
   ],
   "co": [
    "Oura"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "Shapiro 在网络研讨会逐字稿里复盘 2019 年投 Oura：睡眠市场顺风、用户黏性高、戒指在手指动脉处测量比手腕准、订阅让硬件公司有了高毛利的软件收入；顺带提到 Oura 已内置女性健康功能。",
   "vs": "部分",
   "why": "认可戒指是日常健康入口，女性健康只一句带过",
   "cav": "与已收的 2025-05-29「Anatomy of a Deal」是同一机构同一笔投资的另一页面；日期为页面标的活动日，搜索索引标 07-08。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Hormonal Health: A $1 Trillion Frontier",
   "org": "Voima Ventures",
   "au": "",
   "date": "2025-06",
   "url": "https://voimaventures.com/hormonal-health-a-1-trillion-frontier/",
   "seg": [
    "f2"
   ],
   "co": [
    "Natural Cycles（NC° Band）",
    "Oura",
    "Oova",
    "Flo Health"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "Voima 称女性健康市场可能超 1 万亿美元，其中激素健康约 6000 亿美元；认为居家检测与生物传感正走向连续无创监测，预测 3 到 10 年内激素诊断成为企业健康和基层医疗的标配，但皮肤贴片、微针只说「有望」。",
   "vs": "部分",
   "why": "支持连续感知方向，近期落点是居家检测加 AI 解读",
   "cav": "欧洲基金；页面无作者与日期，06 月取自正文 data accessed 2.6.2025；多数市场数字无出处。",
   "r": 2,
   "top": 1
  },
  {
   "t": "Anatomy of a Deal: How AV Evaluated and Invested in Oura",
   "org": "Alumni Ventures",
   "au": "",
   "date": "2025-05-29",
   "url": "https://www.av.vc/blog/an-av-masterclass-anatomy-of-a-deal-how-av-evaluated-and-invested-in-oura",
   "seg": [
    "f9"
   ],
   "co": [
    "Oura"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "AV 复盘 2019 年投 Oura：当初押的是“睡眠是被低估的赛道”，看中 77% 用户戴满 90 天以上的黏性和靠口碑的低获客成本。事后总结：硬件很难，只有加上订阅才稳；Oura 后来扩到经期/生育追踪等女性功能，估值升到 52 亿美元，文中称较入场约 40 倍。",
   "vs": "部分",
   "why": "认可戒指入口与订阅，但强调硬件难、女性功能只是延伸",
   "cav": "并非专门讲女性健康，女性功能只是扩张方向之一；日期取自检索索引，页面无明确日期；署名在页面只显示演讲者 David Shapiro，作者留空。",
   "r": 1,
   "top": 0
  },
  {
   "t": "There's a Growth-Stage Cliff Plaguing Women's Health Startups",
   "org": "Halle Tecco",
   "au": "Halle Tecco, Carolyn Witte",
   "date": "2025-05-07",
   "url": "https://www.halletecco.com/blog/theres-a-growth-stage-cliff-plaguing-womens-health",
   "seg": [
    "all"
   ],
   "co": [
    "Bloomlife"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "2023-2024 年美国女性健康数字健康交易里 81% 是种子和 A 轮，B 轮及以后只占 2.7%，只有 5 家公司拿到 B 轮以上（含孕期监测的 Bloomlife $13M B 轮）。原因：缺可比公司、没有退出、女性基金规模小、投资人性别偏见，所以后期钱断崖。",
   "vs": "部分",
   "why": "后期资金断崖，含孕期监测硬件的公司也难拿 B 轮以上，对硬件规模化偏谨慎",
   "cav": "数据范围是数字健康（不含生物药）；页面日期取自检索索引。",
   "r": 1,
   "top": 1
  },
  {
   "t": "Don't Pee Yourself!",
   "org": "Own the Now",
   "au": "Morgan Johnson",
   "date": "2025-05-01",
   "url": "https://www.ownthenow.com/blog/dont-pee-yourself",
   "seg": [
    "f5"
   ],
   "co": [
    "Elvie（Willow）"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "作者回顾 2015 年投 Elvie 的理由（创始人、Foxconn 制造合作），以及疫情后 VC 对硬件的抵触、两轮高清算优先权融资、创始人离开；称投硬件难、投女性健康更难，两者叠加是罕见的风险。",
   "vs": "相反",
   "why": "用 Elvie 的结局说明女性健康硬件融资与条款都苛刻",
   "cav": "把 Own the Now 判为投资机构、作者为合伙人，依据是文中「我们投了 Elvie」，页面未标头衔；Elvie 破产后的细节为作者个人说法。",
   "r": 2,
   "top": 1
  },
  {
   "t": "A Hitchhiker's Guide to the Personal Health Data Galaxy",
   "org": "Rock Health",
   "au": "",
   "date": "2025-04-28",
   "url": "https://rockhealth.com/rock-weekly/a-hitchhikers-guide-to-the-personal-health-data-galaxy/",
   "seg": [
    "f9"
   ],
   "co": [
    "Oura"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "Rock Health 称 Superpower 融资 3000 万美元，Trellis 推出面向孕产妇的个人健康生态，亚马逊、苹果都在加码健康功能，同时 2024 年调查显示愿意向传统医疗方分享数据的消费者比以往更少。",
   "vs": "部分",
   "why": "个人健康数据加设备在扩张，但与女性只沾边，并强调信任风险",
   "cav": "并非女性专题。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Women in focus: understanding women as digital health consumers",
   "org": "Rock Health",
   "au": "",
   "date": "2025-04-21",
   "url": "https://rockhealth.com/insights/women-in-focus-understanding-women-as-digital-health-consumers/",
   "seg": [
    "f8",
    "f9"
   ],
   "co": [
    "Oura"
   ],
   "kind": "研究报告",
   "region": "海外",
   "gist": "Rock Health 称 2024 年女性健康数字健康融资 6.71 亿美元，占 6.6%。调查里 52% 的女性有可穿戴设备，但智能戒指只有 5%（男性 9%）；他们认为激素贴片等新型可穿戴可能更贴合女性需求。",
   "vs": "部分",
   "why": "女性智能戒指拥有率只有 5%，低于男性 9%，主入口还没形成",
   "cav": "页面未署名，作者留空；融资口径含“部分功能面向女性”的公司。",
   "r": 1,
   "top": 1
  },
  {
   "t": "Innovation in Women's Health 2025",
   "org": "SVB（First Citizens）",
   "au": "Nina Kandilian, Alex Lennox-Miller, Raysa Bousleiman",
   "date": "2025-04-02",
   "url": "https://www.svb.com/trends-insights/reports/womens-health-report/2025/",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "研究报告",
   "region": "海外",
   "gist": "SVB 称 2024 年女性健康风投 26 亿美元，同比增 55%，口径放宽到同类疾病为 107 亿美元；healthtech 占比从 2021 年的 54% 降到 2024 年的 38%，生物药升到 35%。",
   "vs": "部分",
   "why": "钱在从 healthtech 流向生物药，页面没有可穿戴论点",
   "cav": "只读了报告落地页，完整 PDF 需客户开通；页面无日期，04-02 取自报告预览 PDF 的 Published 字样。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Is every company becoming a \"women's health\" company?",
   "org": "The XX Factor（Substack）",
   "au": "Carolyn Witte",
   "date": "2025-03-10",
   "url": "https://thexxfactor.substack.com/p/is-every-company-becoming-a-womens",
   "seg": [
    "f9"
   ],
   "co": [
    "Oura",
    "Natural Cycles（NC° Band）"
   ],
   "kind": "市场分析",
   "region": "海外",
   "gist": "Witte 把「女性健康公司」扩成四类，并把 Oura 当非女性专属公司做对的范本：文中称戒指从 100 万枚卖到 250 万枚，估值 52 亿美元，约 60% 用户为女性，关键是与 Natural Cycles 合作、做多项研究、把隐私放前面。",
   "vs": "一致",
   "why": "明确称 Oura 是女性健康可穿戴的范本",
   "cav": "作者是 Tia 联合创始人而非投资人；页面无日期，03-10 取自检索元数据。",
   "r": 2,
   "top": 0
  },
  {
   "t": "2025 Femtech VC Market Snapshot",
   "org": "PitchBook",
   "au": "",
   "date": "2025-03",
   "url": "https://pitchbook.com/news/reports/2025-femtech-vc-market-snapshot",
   "seg": [
    "all"
   ],
   "co": [
    "Oura"
   ],
   "kind": "研究报告",
   "region": "海外",
   "gist": "PitchBook 称 2020 年以来 femtech 风投交易额超 50 亿美元，仅 2024 年就 12 亿美元；智能戒指等可穿戴被点名为突出品类，会带来个性化追踪和生殖护理进展，预计出现更多独角兽。",
   "vs": "一致",
   "why": "把智能戒指等可穿戴点名为突出品类并预计更多独角兽",
   "cav": "只打开了公开摘要页，正文报告要登录；日期为页面写的更新日 2025-03-04；无署名。",
   "r": 1,
   "top": 1
  },
  {
   "t": "Press release Lauxera-Natural Cycles（Samuel Levy LinkedIn 帖）",
   "org": "Lauxera Capital Partners",
   "au": "Samuel Levy",
   "date": "2024-05-28",
   "url": "https://www.linkedin.com/posts/samuel-levy-543b001_press-release-lauxera-natural-cycles-activity-7201644825408872448-DZMq",
   "seg": [
    "f1"
   ],
   "co": [
    "Natural Cycles（NC° Band）"
   ],
   "kind": "投资理由",
   "region": "海外",
   "gist": "Levy 称 Natural Cycles 是数字避孕里获 FDA 批准、可报销的品类龙头，Series C 5500 万美元用于商业加速、新产品和医保报销自动化，主张是让女性用 AI 而不是激素或有创手段掌控生育。",
   "vs": "部分",
   "why": "支持算法给结论，但是体温加 app，不是靠穿戴硬件成为入口",
   "cav": "LinkedIn 短帖，更像公告；页面无日期，2024-05-28 取自检索索引；Lauxera 为法国 PE 基金。",
   "r": 2,
   "top": 0
  },
  {
   "t": "The femtech market map",
   "org": "CB Insights",
   "au": "",
   "date": "2024-03-28",
   "url": "https://www.cbinsights.com/research/femtech-womens-healthcare-market-map/",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "市场分析",
   "region": "海外",
   "gist": "CB Insights 称女性健康科技融资 2023 年从 14 亿美元跌到 6.48 亿美元，但更年期科技和虚拟/混合护理融资激增；图谱收录 19 类、199 家公司。",
   "vs": "部分",
   "why": "只确认更年期与虚拟护理在涨，文字没提可穿戴",
   "cav": "图谱本体是图片未读到公司名；同日另一简报写「127 家」，与正文 199 家不一致，引用以正文为准。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Can investors help women's health break through the glass ceiling?",
   "org": "Deloitte Center for Health Solutions",
   "au": "Peter Micca, Christine Chang",
   "date": "2024-02-27",
   "url": "https://www.deloitte.com/global/en/insights/industry/health-care/health-tech-and-womens-health-investment-trends.html",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "研究报告",
   "region": "海外",
   "gist": "Deloitte 称 2022 到 2023 年美国健康科技风投降 27%，女性健康却增 5%，2023 年为 4.81 亿美元、21 笔，占医疗风投的 2%；2023 年调查里愿向医疗机构分享健康数据的女性占 43%，男性 57%。",
   "vs": "部分",
   "why": "女性融资回升，但女性对分享设备数据更犹豫，是可穿戴入口的隐私阻力",
   "cav": "与已收的 Deloitte 2026 两篇不同；基于 PitchBook 数据，没有可穿戴专论。",
   "r": 2,
   "top": 0
  },
  {
   "t": "Closing the women's health gap: A $1 trillion opportunity to improve lives and economies",
   "org": "McKinsey Health Institute",
   "au": "McKinsey Health Institute 团队（含 Lucy Pérez、Anouk Petersen、Valentina Sartori 等）",
   "date": "2024-01-16",
   "url": "https://www.mckinsey.de/mhi/our-insights/closing-the-womens-health-gap-a-1-trillion-dollar-opportunity-to-improve-lives-and-economies",
   "seg": [
    "all"
   ],
   "co": [],
   "kind": "研究报告",
   "region": "海外",
   "gist": "McKinsey 称女性比男性多 25% 的时间处于不健康状态，补上差距到 2040 年每年可为全球经济多增至少 1 万亿美元；女性健康只占数字健康融资的 3%，并看好数字健康方案。",
   "vs": "部分",
   "why": "认可大市场，但是宏观总论，没有可穿戴论点",
   "cav": "英文站页面 404，读的是 McKinsey 德国站镜像；日期取自检索，WEF 称 01-17 发布。",
   "r": 2,
   "top": 0
  }
 ]
}